Antitumor activity of E7123 in an in vivo xenograft model and FA protein signaling in DLBCL patient samples. (A) Swiss-nude mice were injected in the flank with 10 × 106 HT cells and treated with vehicle or 100 mg/kg of E7123 as described in “Animal experiments.” Tumor volumes were plotted against days of treatment. A significant reduction of tumor volume can be observed after 22 doses. Error bars represent SD. Statistical analysis was performed using the Mann-Whitney test. *P < .05. (B) Weights of each mouse were monitored daily, and the mean weight of each group was plotted against days of treatment to assess E7123 toxicity. (C) Immunoblot analyses of p130Cas, HEF1, FAK, PYK2, and LYN in whole protein extracts of 29 DLBCL patient samples. Positive control samples for each particular protein are marked with a circled “C.” GAPDH was used as a control for protein loading. (D) Immunoblot of phosphorylated FAK, AKT, and Mcl-1 on 4 DLBCL patient samples. GAPDH was used as a control for protein loading.
